o2h Ventures has been shortlisted for the EISA Impact Award for the second consecutive year. This nomination showcases the significant impact we are making within the early-stage biotech industry through our investments in the Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS).
At o2h Ventures, we have a strong pipeline of 30+ innovative and exciting early-stage biotechs focusing on novel drug therapeutics and AI/ML enablers. These companies are focused on addressing critical and unmet health needs, including fatal diseases such as cancer and idiopathic pulmonary fibrosis (IPF), mental health conditions like depression, crucial diseases affecting the ear and eye, and infectious diseases. By investing in pure-play discovery and therapeutics we aim to profoundly impact patients’ health in the long run.
Through our open human health Knowledge Intensive EIS and SEIS funds, we actively seek out companies developing assets for clinical trials and proof of concept and supporting companies having AI/ML and quantum computing to advance drug discovery.
The annual EISA Awards celebrate the outstanding achievements of members of the EIS and SEIS community. From entrepreneurs to investors, legal experts to financial advisors (and more), the community is a broad church.
To know more, click here.
About Enterprise Investment Scheme Association
The UK’s trade body for EIS and SEIS – the Enterprise Investment Scheme and Seed Enterprise Investment Scheme.
EISA is a highly effective not-for-profit organization which exists to aid the provision of capital to UK small and medium-sized enterprises (SMEs) through the Enterprise Investment Scheme (EIS) and the Seed Enterprise Investment Scheme (SEIS).
EISA works closely with HM Treasury, HM Revenue and Customs, Government Ministers, MPs and the FCA to enhance the EIS and promote the benefits of the scheme to investors and companies using EIS/SEIS and their respective advisers. To know more, please visit here
